JP2019528677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528677A5 JP2019528677A5 JP2018566591A JP2018566591A JP2019528677A5 JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5 JP 2018566591 A JP2018566591 A JP 2018566591A JP 2018566591 A JP2018566591 A JP 2018566591A JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- seq
- composition
- axl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 101150022345 GAS6 gene Proteins 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610902.7A GB201610902D0 (en) | 2016-06-22 | 2016-06-22 | Anti-Axl Antagonistic Antibodies |
| GB1610902.7 | 2016-06-22 | ||
| PCT/EP2017/065313 WO2017220695A1 (en) | 2016-06-22 | 2017-06-21 | Anti-axl antagonistic antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528677A JP2019528677A (ja) | 2019-10-17 |
| JP2019528677A5 true JP2019528677A5 (enExample) | 2020-07-30 |
| JP7071935B2 JP7071935B2 (ja) | 2022-05-19 |
Family
ID=56895047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566591A Active JP7071935B2 (ja) | 2016-06-22 | 2017-06-21 | 抗Ａｘｌアンタゴニスト抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11198734B2 (enExample) |
| EP (1) | EP3475305A1 (enExample) |
| JP (1) | JP7071935B2 (enExample) |
| KR (1) | KR102458196B1 (enExample) |
| CN (2) | CN116903748A (enExample) |
| AU (1) | AU2017281326A1 (enExample) |
| CA (1) | CA3025729A1 (enExample) |
| GB (1) | GB201610902D0 (enExample) |
| MX (1) | MX2018016096A (enExample) |
| WO (1) | WO2017220695A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX390849B (es) * | 2014-12-18 | 2025-03-21 | Bergenbio Asa | Anticuerpos antagonistas anti-axl. |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| NL2024108B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses |
| MY209381A (en) * | 2020-02-28 | 2025-07-04 | Servier Lab | Anti-axl antibodies and compositions |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| CN115916344A (zh) | 2020-04-08 | 2023-04-04 | 卑尔根生物股份公司 | 用于抗病毒疗法的axl抑制剂 |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| AU2022211971A1 (en) | 2021-01-29 | 2023-08-10 | Illimis Therapeutics, Inc. | Fusion molecule having non-inflammatory phagocytosis inducing activity |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| EP4357365A4 (en) * | 2021-06-16 | 2025-06-04 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibodies against AXL protein and antigen-binding fragment thereof, as well as methods of production and use thereof |
| WO2022269605A1 (en) * | 2021-06-24 | 2022-12-29 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| EP4572854A2 (en) * | 2022-08-18 | 2025-06-25 | Biolegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| JP5769969B2 (ja) | 2007-11-12 | 2015-08-26 | ユー３・ファーマ・ゲーエムベーハー | Ａｘｌ抗体 |
| EP2228392A4 (en) | 2007-11-15 | 2012-05-02 | Chugai Pharmaceutical Co Ltd | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO AN UNCONTROLLED GENE (ANEXELEKTO) AND USE THEREOF |
| WO2010130751A1 (en) | 2009-05-11 | 2010-11-18 | U3 Pharma Gmbh | Humanized axl antibodies |
| WO2010131733A1 (ja) * | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
| WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| BR112013032899A2 (pt) * | 2011-06-22 | 2017-01-24 | Inserm Inst Nat De La Santé Et De La Rech Médicale | anticorpos anti-axl e utilizações dos mesmos |
| AU2012273954A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| CN104955842B (zh) * | 2012-11-05 | 2018-04-10 | 皮埃尔法布雷医药公司 | 抗原结合蛋白及其作为定位产品用于治疗癌症的用途 |
| WO2014144553A1 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
| JP2016518382A (ja) | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Ａｘｌ抗体薬物複合体および癌の治療のためのその使用 |
| KR102448454B1 (ko) * | 2014-01-29 | 2022-09-28 | 다나-파버 캔서 인스티튜트 인크. | Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체 |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| US9986723B2 (en) | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
| MX390849B (es) * | 2014-12-18 | 2025-03-21 | Bergenbio Asa | Anticuerpos antagonistas anti-axl. |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| US11159088B2 (en) * | 2019-06-19 | 2021-10-26 | Appulse Power Inc. | Dual path and mode start-up circuit |
| GB202004189D0 (en) * | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
-
2016
- 2016-06-22 GB GBGB1610902.7A patent/GB201610902D0/en not_active Ceased
-
2017
- 2017-06-21 US US16/098,933 patent/US11198734B2/en not_active Expired - Fee Related
- 2017-06-21 KR KR1020187036968A patent/KR102458196B1/ko active Active
- 2017-06-21 CN CN202310799984.3A patent/CN116903748A/zh active Pending
- 2017-06-21 CN CN201780038590.9A patent/CN109311997B/zh not_active Expired - Fee Related
- 2017-06-21 AU AU2017281326A patent/AU2017281326A1/en not_active Abandoned
- 2017-06-21 WO PCT/EP2017/065313 patent/WO2017220695A1/en not_active Ceased
- 2017-06-21 MX MX2018016096A patent/MX2018016096A/es unknown
- 2017-06-21 CA CA3025729A patent/CA3025729A1/en active Pending
- 2017-06-21 EP EP17732875.4A patent/EP3475305A1/en not_active Withdrawn
- 2017-06-21 JP JP2018566591A patent/JP7071935B2/ja active Active
-
2021
- 2021-11-02 US US17/516,916 patent/US11732048B2/en active Active
-
2023
- 2023-06-29 US US18/216,085 patent/US20240190972A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528677A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| HRP20241381T1 (hr) | Nova anti-pd-1 protutijela | |
| NZ752294A (en) | Cd3 binding antibodies | |
| JP2020525032A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2012254092A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| JP2020504076A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2016536342A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2020516305A5 (enExample) | ||
| JP2018536393A5 (enExample) |